Log In
Print this Print this

PRS-010 (formerly OncoCal l)

  Manage Alerts
Collapse Summary General Information
Company Pieris Pharmaceuticals Inc.
DescriptionAnticalin targeting CTLA-4
Molecular Target Cytotoxic T-lymphocyte associated protein 4 (CTLA4) (CD152)
Mechanism of ActionCTLA-4 (CD152) antagonist
Therapeutic ModalityBiologic: Protein
Latest Stage of DevelopmentPreclinical
Standard IndicationHematologic malignancies
Indication DetailsTreat hematologic malignancies
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today